Bringing Hope to Families Affected by NF2-Related Schwannomatosis
Giving Tuesday Goal: $50,000 to Kickstart the Next Step Toward a Cure
NF2-related Schwannomatosis (NF2-SWN) is a rare disease affecting 1 in 28,000 people. Individuals with NF2-SWN develop multiple tumors along nerves in the brain, spinal cord, and other parts of the body. These tumors, known as schwannomas, meningiomas, and ependymomas, cause serious complications such as hearing loss, balance difficulties, paralysis, vision impairment, and mental health struggles. NF2-SWN has a substantial negative impact on quality of life and dramatically reduces life expectancy.
There is no cure. Families affected by NF2-SWN urgently need safer, more effective therapies that address the underlying cause of the disease. Gene therapy is the only approach that directly targets the underlying genetic cause of NF2-SWN.
A Promising Path Forward: AAV9-NF2 Gene Addition Therapy
Since 2019, NF2 BioSolutions has partnered with researchers at Nationwide Children’s Hospital in Ohio to develop an innovative gene therapy known as AAV9-NF2 Gene Addition Therapy.
This therapy uses a harmless, engineered viral vector (AAV9) to deliver a healthy copy of the NF2 gene, enabling production of the essential protein Merlin. In NF2-SWN, mutations in the NF2 gene prevent the body from producing enough Merlin, a protein that regulates cell growth, leading to tumor development.
NF2 BioSolutions' approach is unique because it aims to restore Merlin production to healthy levels in all NF2-affected cell types. By doing so, it could help prevent or slow tumor growth throughout the nervous system.
NF2 BioSolutions has successfully designed and validated the therapy in the laboratory at Nationwide Children’s Hospital. Manufacturing the AAV9 vectors is estimated at $2.2 million. Our immediate goal is to raise $50,000 by January 2026 to launch production.
Optionally, you can save your purchase to your account by Signing in.
If you don’t have an account, you can Sign up to create one.